During a Case-Based Roundtable event, Laura Huppert, MD, discussed data and considerations around using T-DXd in breast ...

Leerink Partners maintained an Outperform rating on Arvinas Inc. (NASDAQ:ARVN) but reduced the price target from $62.00 to ...

A phase 3 clinical trial has shown that adding a targeted immunotherapy drug to chemotherapy dramatically improved – almost ...

After a second breast cancer diagnosis at 61, I faced 17 rounds of chemo, surgery and radiation, changing my perspective on life and leading to a new normal.

The U.S. Food and Drug Administration has approved Enhertu (trastuzumab deruxtecan) for the treatment of adult patients with ...

In a report released on January 29, Andrew Berens from Leerink Partners maintained a Hold rating on Zentalis Pharmaceuticals (ZNTL – Research ...

The researchers found that imlunestrant prolonged progression-free survival (PFS) when compared to standard care in patients with ESR1 mutations, but there was no PFS benefit observed in the overall ...

Live webcasts of these presentations will be available in the Events and Presentations section of Olema’s investor relations website at ir.olema.com. The webcasts will be archived for at least 30 days ...

Analyst Derek Archila from Wells Fargo maintained a Hold rating on Zentalis Pharmaceuticals (ZNTL – Research Report) and decreased the price ...

The FDA approved trastuzumab deruxtecan for adult patients with unresectable or metastatic HER2-low or HER2-ultralow breast ...